COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation

Area of Science:

• Hematology
• Infectious Diseases
• Public Health

Background:

• Patients with haemoglobinopathies (thalassaemia, sickle cell disease) are at high risk for severe COVID-19 complications.
• Limited epidemiological data exists on SARS-CoV-2 infection in this vulnerable population.
• The COVID-19 pandemic poses significant challenges to haemoglobinopathy patient care.

Purpose of the Study:

• To outline key challenges in managing haemoglobinopathies during the COVID-19 pandemic.
• To identify knowledge gaps in SARS-CoV-2 infection among these patients.
• To propose evidence-based strategies for adapting haemoglobinopathy care.

Main Methods:

• Review of available evidence and expert opinions on COVID-19 impact on haemoglobinopathies.
• Focus on transfusion-dependent and non-transfusion-dependent thalassaemia management.
• Analysis of risk levels, care adaptation, blood transfusion safety, and supply chain issues.

Main Results:

• Identified critical areas for managing haemoglobinopathy patients during the pandemic.
• Highlighted the need for adapting clinical practices and ensuring blood supply.
• Addressed lifestyle and nutritional considerations for affected individuals.

Conclusions:

• The proposed strategies offer a framework for managing haemoglobinopathies during pandemics.
• These measures can guide the adaptation of care for patients requiring regular hospital visits.
• The blueprint is applicable to managing other chronic conditions during health crises.